Forever Labs will dedicate resources to continue pioneering stem cell research breakthroughs and accelerate brand development.
Founded in 2015, Forever Labs is transforming the healthcare industry by preserving healthy stem cells for future therapies that combat age-related diseases, as well as aging itself.
Its proprietary procedure involves a certified Forever Labs physician collecting one's mesenchymal stem cells (MSCs), which have the ability to stimulate tissues to grow and repair themselves when most needed.
After a brief outpatient procedure, the stem cells are cryogenically frozen and safely stored agnostically in an FDA-compliant clinical-grade biorepository until needed.
Forever Labs was created to preserve healthy stem cells to later rejuvenate one's MSC population to significantly delay the onset of those age-related diseases and extend a healthy lifespan.
AstraZeneca's IMFINZI combination receives US Priority Review for muscle-invasive bladder cancer
Novotech to acquire Agilex Biolabs from Healius
ACROBiosystems launches CHO-Direct and ACRO AIx to accelerate AI-driven drug discovery
UChicago Medicine completes construction phase of new cancer facility
Viking Therapeutics plans offerings of common stock and convertible senior notes
Astellas doses first patient in Phase 3 lung cancer study
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Ondine Biomedical deployssteriwave across five Southern Ontario hospitals
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
AstronauTx receives funding to explore sleep-based approaches for Parkinson's disease
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Genentech reports positive Phase II results for enicepatide in type 2 diabetes